Publications by authors named "Celine Wilke"

Claim this Profile
R
Ruxolitinib Versus Best Available Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: Final Analysis From the Randomized Phase III REACH2 Trial.
Mohamad Mohty, Gerard Socié, Jeff Szer, Dietger Niederwieser, Jason Butler, Celine Wilke

J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imaging Efficacy of [F]CTT1057 PET for the Detection of PSMA-Positive Tumors Using Histopathology as Standard of Truth: Results from the GuideView Phase 2/3 Prospective Multicenter Study.
Andrei Iagaru, Jose F Suarez, Spencer Behr, Rahul Aggarwal, Pilar Paredes, Celine Wilke

J Nucl Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imaging Efficacy of [F]CTT1057 PET/CT in Patients with Biochemically Recurrent Prostate Cancer: Results from GuidePath-A Phase 3, Prospective Multicenter Study.
Stefano Fanti, Javier Jesus Robles Barba, Spencer Behr, Tobias Maurer, Pilar Paredes, Celine Wilke

J Nucl Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multivariable models of outcomes with [Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial.
Ken Herrmann, Andrei Gafita, Johann S de Bono, Oliver Sartor, Kim N Chi, Celine Wilke

EClinicalMedicine· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial.
Michael J Morris, Daniel Castellano, Ken Herrmann, Johann S de Bono, Neal D Shore, Celine Wilke

Lancet· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety Analyses of the Phase 3 VISION Trial of [Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer.
Kim N Chi, Andrew J Armstrong, Bernd J Krause, Ken Herrmann, Kambiz Rahbar, Celine Wilke

Eur Urol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of blood biomarkers in steroid-refractory or steroid-dependent acute graft-versus-host disease: a REACH2 analysis.
Gerard Socié, Dietger Niederwieser, Nikolas von Bubnoff, Mohamad Mohty, Jeff Szer, Celine Wilke

Blood· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical studies on the use of a P-selectin-blocking monoclonal antibody to halt progression of myelofibrosis in the Gata1 mouse model.
Paola Verachi, Francesca Gobbo, Fabrizio Martelli, Mario Falchi, Antonio di Virgilio, Celine Wilke

Exp Hematol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease.
Robert Zeiser, Nikolas von Bubnoff, Jason Butler, Mohamad Mohty, Dietger Niederwieser, Celine Wilke

N Engl J Med· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alpelisib for -Mutated, Hormone Receptor-Positive Advanced Breast Cancer.
Fabrice André, Eva Ciruelos, Gabor Rubovszky, Mario Campone, Sibylle Loibl, Celine Wilke

N Engl J Med· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors.
Jordi Rodon, Giuseppe Curigliano, Jean-Pierre Delord, Wael Harb, Analia Azaro, Celine Wilke

Oncotarget· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer.
Michail Ignatiadis, Dimitrios Zardavas, Marc Lemort, Celine Wilke, Marie-Catherine Vanderbeeken

PLoS One· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis